Emergent BioSolutions has been developing protective solutions for public health threats including smallpox, mpox, botulism, and anthrax for over 25 years, according to the press release statement.

Final analysis of the INTRIGUE trial shows ripretinib offers similar survival rates and better safety compared to sunitinib ...

Investing.com -- Emergent BioSolutions Inc (NYSE: EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication ...

Emergent also secured a $62.4 million contract modification for its botulism antitoxin with the U.S. Department of Health and Human Services, reinforcing its role in medical countermeasures.

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for ...

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

Rentosertib, an AI-generated small molecule targeting Traf2- and Nck-interacting kinase, was safe and improved FVC in ...

Planned Parenthood stands to lose a huge portion of its federal funding under President Trump’s “big, beautiful bill,” which could result in the closure of up to 200 clinics, according ...

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin ...

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.